---
title: "Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 10-Q: FY2025 Q2 Revenue: USD 16.41 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253099225.md"
datetime: "2025-08-14T20:28:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253099225.md)
  - [en](https://longbridge.com/en/news/253099225.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253099225.md)
---

# Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 10-Q: FY2025 Q2 Revenue: USD 16.41 M

Revenue: As of FY2025 Q2, the actual value is USD 16.41 M.

EPS: As of FY2025 Q2, the actual value is USD 0.45.

EBIT: As of FY2025 Q2, the actual value is USD -36.47 M.

### Segment Revenue

-   **Journey Medical Corporation (JMC)**: Net product revenue was $15.0 million for the three months ended June 30, 2025, compared to $14.9 million for the same period in 2024. For the six months ended June 30, 2025, net product revenue was $28.1 million, compared to $27.9 million in 2024.

### Operational Metrics

-   **Loss from Operations**: The consolidated loss from operations was $36.5 million for the three months ended June 30, 2025, compared to $27.8 million for the same period in 2024. For the six months ended June 30, 2025, the loss from operations was $58.8 million, compared to $64.4 million in 2024.
-   **Research and Development Expenses**: R&D expenses decreased to $8.1 million for the three months ended June 30, 2025, from $12.7 million in 2024. For the six months ended June 30, 2025, R&D expenses were $12.1 million, down from $37.5 million in 2024.
-   **Selling, General and Administrative Expenses**: These expenses increased to $38.8 million for the three months ended June 30, 2025, from $20.8 million in 2024. For the six months ended June 30, 2025, these expenses were $64.4 million, up from $38.8 million in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the six months ended June 30, 2025, net cash used in operating activities was $47.1 million, compared to $47.2 million in 2024.
-   **Net Cash Provided by Financing Activities**: For the six months ended June 30, 2025, net cash provided by financing activities was $56.7 million, compared to $42.1 million in 2024.

### Unique Metrics

-   **Gain from Deconsolidation of Subsidiary**: A gain of $27.1 million was recognized from the deconsolidation of Checkpoint due to its acquisition by Sun Pharma in May 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: Fortress Biotech plans to continue focusing on acquiring and advancing assets to enhance long-term value through product revenue, equity holdings, and dividend and royalty revenue streams. The company aims to leverage its network to identify promising products for acquisition and development.
-   **Non-Core Business**: The company is exploring strategic partnerships and collaborations to support research and development, including joint ventures and out-licensing opportunities.

### Related Stocks

- [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md)

## Related News & Research

- [Mark Zuckerberg's Net Worth Crashes $31 Billion This Year, But Analysts Still Bullish on Meta](https://longbridge.com/en/news/289670977.md)
- [Qnity Electronics’ New AI Chip Materials Prompt Fresh Look At Rich Valuation](https://longbridge.com/en/news/289656218.md)
- [Zscaler (ZS) Stock After 57% Slide Is The Market Overreacting On Valuation](https://longbridge.com/en/news/289656354.md)
- [Spotify (SPOT) Stock After Recent Volatility Is The Current Price Still Justified](https://longbridge.com/en/news/289656399.md)
- [The Bull Case For Textron (TXT) Could Change Following New EV Battery Enclosure Win - Learn Why](https://longbridge.com/en/news/289655818.md)